Publications by authors named "Angela Maria Londono"
Article Synopsis
- Atopic dermatitis, also known as eczema, is a chronic skin condition that causes itching and inflammation, and there's limited data on its impact in Colombia.
- A study using data from Colombia's national claims database (SISPRO) from 2015-2020 aimed to analyze the epidemiology and healthcare resource use related to atopic dermatitis.
- Findings indicated a rise in both the incidence and prevalence of the condition during 2018-2019, leading to increased medical consultations and treatments, with topical and systemic corticoids being the most common medications prescribed.
Introduction: About 80-95% of patients infected with the human immunodeficiency virus (HIV) develop skin manifestations, which are markers of the patients’ immune status.
Objective: To describe the dermatologic manifestations and the clinical and sociodemographic factors of hospitalized patients diagnosed with HIV and their correlation with CD4 T-lymphocyte count.
Materials And Methods: We conducted an observational, cross-sectional, and retrospective study of the medical records of 227 adult patients with HIV diagnosis evaluated by dermatology in a hospital in Medellín, Colombia.
Therapeutic failure in moderate and severe psoriasis patients in a health institution - a transversal study of prevalence and demographic determinants.
Daniel Montoya-Londoño Carlos Alberto Gómez-Mercado Jorge Iván Estrada-Acevedo Juliana Madrigal-Cadavid Angela Segura
J Dermatolog Treat
September 2022
Article Synopsis
- - Psoriasis is a chronic condition that greatly affects quality of life, influenced by genetic and environmental factors, with no known cure but various treatment options available that often fail to control symptoms effectively.
- - A study evaluated 1,051 patients with moderate to severe psoriasis to determine factors linked to treatment failure, discovering associations with gender, type of therapy, age, treatment duration, and health-related quality of life.
- - Results indicate that males and those on biologic therapies are more likely to experience treatment failure, while older age and longer treatment duration reduce the likelihood of failure; additionally, higher DLQI scores correlate with increased risk of treatment failure.